首页 > 最新文献

The Journal of Prevention of Alzheimer's Disease最新文献

英文 中文
Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators 阿尔茨海默病治疗亟待进步--欧洲阿尔茨海默病联合会(EADC)研究人员的立场声明
IF 6.4 Q2 BUSINESS Pub Date : 2024-08-11 DOI: 10.14283/jpad.2024.153
Frank Jessen, M. G. Kramberger, D. Angioni, D. Aarsland, M. Balasa, K. Bennys, M. Boada, M. Boban, A. Chincarini, L. Exalto, A. Felbecker, K. Fliessbach, G. B. Frisoni, A. J. Garza-Martínez, T. Grimmer, B. Hanseeuw, J. Hort, A. Ivanoiu, S. Klöppel, L. Krajcovicova, B. McGuinness, P. Mecocci, A. de Mendonca, A. Nous, P.-J. Ousset, C. Paquet, R. Perneczky, O. Peters, M. Tabuas-Pereira, F. Piazza, D. Plantone, M. Riverol, A. Ruiz, G. Sacco, I. Santana, N. Scarmeas, E. Solje, E. Stefanova, S. Sutovsky, W. van der Flier, T. Welsh, A. Wimo, B. Winblad, L. Frölich, S. Engelborghs

β-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer’s disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer’s Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now. Given the complexity of AD it is unlikely that molecular single-target treatments will achieve substantially larger effects than those seen with current β-amyloid-targeting antibodies. Larger effects will most likely only be achieved incrementally by continuous optimization of molecular approaches, patient selection and combinations therapies. To be successful in this regard, drug development must be informed by the use of innovative treatments in real world practice, because full understanding of all facets of novel treatments requires experience and data of real-world care beyond those of clinical trials. Regarding the antibodies under discussion we consider their effects meaningful and potential side effects manageable. We assume that the number of eventually treated patient will only be a fraction of all early AD patients due to narrow eligibility criteria and barriers of access. We strongly endorse the use of these new compound in clinical practice in selected patients with treatment documentation in registries. We understand this as a critical step in advancing the field of AD treatment, and in shaping the health care systems for the new area of molecular-targeted treatment of neurodegenerative diseases.

β-淀粉样蛋白靶向抗体代表了第一代有效的阿尔茨海默病(AD)因果治疗方法,可以说是历史性的研究里程碑。然而,其效果大小、副作用、实施挑战和成本引发了对其整体价值的争论。在这份立场声明中,欧洲阿尔茨海默病联盟(EADC)的临床医生们讨论了现在将这些新疗法引入临床治疗的重要意义。鉴于阿尔茨海默病的复杂性,分子单靶点治疗不太可能取得比目前的β-淀粉样蛋白靶向抗体更大的疗效。更大的疗效很可能只能通过不断优化分子方法、患者选择和组合疗法来逐步实现。要想在这方面取得成功,药物开发必须参考创新疗法在现实世界中的使用情况,因为要充分了解新型疗法的方方面面,除了临床试验之外,还需要现实世界中的治疗经验和数据。关于正在讨论的抗体,我们认为其效果是有意义的,潜在的副作用是可控的。我们假定,由于资格标准狭窄和获得治疗的障碍,最终接受治疗的患者人数仅占所有早期AD患者的一小部分。我们强烈支持在临床实践中对选定的患者使用这些新化合物,并在登记册中记录治疗情况。我们认为这是推进 AD 治疗领域的关键一步,也是为神经退行性疾病分子靶向治疗这一新领域建立医疗保健系统的关键一步。
{"title":"Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators","authors":"Frank Jessen, M. G. Kramberger, D. Angioni, D. Aarsland, M. Balasa, K. Bennys, M. Boada, M. Boban, A. Chincarini, L. Exalto, A. Felbecker, K. Fliessbach, G. B. Frisoni, A. J. Garza-Martínez, T. Grimmer, B. Hanseeuw, J. Hort, A. Ivanoiu, S. Klöppel, L. Krajcovicova, B. McGuinness, P. Mecocci, A. de Mendonca, A. Nous, P.-J. Ousset, C. Paquet, R. Perneczky, O. Peters, M. Tabuas-Pereira, F. Piazza, D. Plantone, M. Riverol, A. Ruiz, G. Sacco, I. Santana, N. Scarmeas, E. Solje, E. Stefanova, S. Sutovsky, W. van der Flier, T. Welsh, A. Wimo, B. Winblad, L. Frölich, S. Engelborghs","doi":"10.14283/jpad.2024.153","DOIUrl":"https://doi.org/10.14283/jpad.2024.153","url":null,"abstract":"<p>β-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer’s disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer’s Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now. Given the complexity of AD it is unlikely that molecular single-target treatments will achieve substantially larger effects than those seen with current β-amyloid-targeting antibodies. Larger effects will most likely only be achieved incrementally by continuous optimization of molecular approaches, patient selection and combinations therapies. To be successful in this regard, drug development must be informed by the use of innovative treatments in real world practice, because full understanding of all facets of novel treatments requires experience and data of real-world care beyond those of clinical trials. Regarding the antibodies under discussion we consider their effects meaningful and potential side effects manageable. We assume that the number of eventually treated patient will only be a fraction of all early AD patients due to narrow eligibility criteria and barriers of access. We strongly endorse the use of these new compound in clinical practice in selected patients with treatment documentation in registries. We understand this as a critical step in advancing the field of AD treatment, and in shaping the health care systems for the new area of molecular-targeted treatment of neurodegenerative diseases.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"11 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142197471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform 在 Quanterix HD-X 平台上使用 ALZpath pTau217 检测法验证人血浆、血清和脑脊液中磷-Tau 217 (pTau217) 的超灵敏定量方法
IF 6.4 Q2 BUSINESS Pub Date : 2024-08-10 DOI: 10.14283/jpad.2024.155
H. Zhang, J. Liu, N. Zhang, A. Jeromin, Zhongping John Lin

Background

Both blood (plasma and serum) and CSF tau phosphorylated at Threonine 217 (pTau217) have been shown to be able to discriminate early to mild Alzheimer’s disease (AD) from non-AD neurodegenerative disorders and healthy controls with high sensitivity and specificity.

Objectives

We report the full validation of the ALZpath ultra-sensitive pTau217 research-use only (RUO) assays for human EDTA plasma, serum, and CSF using the Quanterix Simoa HD-X platform, in support of clinical trials and early diagnosis of Alzheimer’s disease.

Methods

The ALZpath pTau217 Simoa Advantage v2 kit from ALZpath/Quanterix was used for method development and validation of pTau217 in human plasma, serum, and CSF. All three method validations have followed the 2018 FDA BMV and 2022 ICH M10 guidelines.

Results

Validation of pTau217 quantitation in human plasma, serum, and CSF demonstrated that the validated pTau217 assay has an analytical LLOQ of 0.00977 pg/mL. It is one of the most sensitive assays with a minimal required sample volume of 33.3 µl for plasma and serum, and 5 µl for CSF, and is relatively cost-effective, compared to the currently published data. The minimum required dilution (MRD) for plasma, serum, and CSF were determined. The analyte passed short-term stability tests. It was also tolerant of moderate hemolytic, and lipemic interferences in plasma and serum. pTau217 was detected in 100% of tested healthy control plasma, 90.0% of healthy control serum, 92.3% of healthy control CSF samples, and 100% of AD plasma and CSF samples. The validated assay was successfully applied in the analysis of AD samples, with data showing dramatic differences in the pTau217 levels between healthy control subjects and AD patients in both plasma and CSF.

Conclusion

Validation of the ALZpath pTau217 Simoa assay in human plasma, serum, and CSF demonstrates ultra sensitivity, high accuracy, and assay robustness. Together with other established and sensitive assays for pTau181, GFAP, and NfL, these assays have immediate utility for application in clinical trials and can play a role in the early diagnosis of neurodegenerative diseases.

背景血液(血浆和血清)和脑脊液中苏氨酸217磷酸化的tau(pTau217)已被证明能以高灵敏度和特异性区分早期至轻度阿尔茨海默病(AD)与非AD神经退行性疾病和健康对照组。方法ALZpath/Quanterix公司的ALZpath pTau217 Simoa Advantage v2试剂盒用于开发和验证人血浆、血清和脑脊液中pTau217的检测方法。结果人血浆、血清和脑脊液中pTau217的定量验证表明,经过验证的pTau217检测方法的分析LLOQ为0.00977 pg/mL。它是灵敏度最高的检测方法之一,血浆和血清所需的最小样本量为 33.3 µl,CSF 为 5 µl,与目前公布的数据相比,成本效益相对较高。确定了血浆、血清和脑脊液的最小所需稀释度(MRD)。分析物通过了短期稳定性测试。pTau217 在100%的健康对照血浆、90.0%的健康对照血清、92.3%的健康对照脑脊液样本以及100%的AD血浆和脑脊液样本中都能检测到。结论 ALZpath pTau217 Simoa 检测法在人血浆、血清和脑脊液中的验证表明,该检测法具有超灵敏度、高准确度和检测稳健性。这些检测方法与其他成熟、灵敏的 pTau181、GFAP 和 NfL 检测方法一起,可立即应用于临床试验,并可在神经退行性疾病的早期诊断中发挥作用。
{"title":"Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform","authors":"H. Zhang, J. Liu, N. Zhang, A. Jeromin, Zhongping John Lin","doi":"10.14283/jpad.2024.155","DOIUrl":"https://doi.org/10.14283/jpad.2024.155","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Both blood (plasma and serum) and CSF tau phosphorylated at Threonine 217 (pTau217) have been shown to be able to discriminate early to mild Alzheimer’s disease (AD) from non-AD neurodegenerative disorders and healthy controls with high sensitivity and specificity.</p><h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>We report the full validation of the ALZpath ultra-sensitive pTau217 research-use only (RUO) assays for human EDTA plasma, serum, and CSF using the Quanterix Simoa HD-X platform, in support of clinical trials and early diagnosis of Alzheimer’s disease.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The ALZpath pTau217 Simoa Advantage v2 kit from ALZpath/Quanterix was used for method development and validation of pTau217 in human plasma, serum, and CSF. All three method validations have followed the 2018 FDA BMV and 2022 ICH M10 guidelines.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Validation of pTau217 quantitation in human plasma, serum, and CSF demonstrated that the validated pTau217 assay has an analytical LLOQ of 0.00977 pg/mL. It is one of the most sensitive assays with a minimal required sample volume of 33.3 µl for plasma and serum, and 5 µl for CSF, and is relatively cost-effective, compared to the currently published data. The minimum required dilution (MRD) for plasma, serum, and CSF were determined. The analyte passed short-term stability tests. It was also tolerant of moderate hemolytic, and lipemic interferences in plasma and serum. pTau217 was detected in 100% of tested healthy control plasma, 90.0% of healthy control serum, 92.3% of healthy control CSF samples, and 100% of AD plasma and CSF samples. The validated assay was successfully applied in the analysis of AD samples, with data showing dramatic differences in the pTau217 levels between healthy control subjects and AD patients in both plasma and CSF.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Validation of the ALZpath pTau217 Simoa assay in human plasma, serum, and CSF demonstrates ultra sensitivity, high accuracy, and assay robustness. Together with other established and sensitive assays for pTau181, GFAP, and NfL, these assays have immediate utility for application in clinical trials and can play a role in the early diagnosis of neurodegenerative diseases.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"6 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141929869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of the COVID-19 Pandemic on the Number of New Dementia Diagnoses and the Quality of Dementia Diagnostics and Treatment COVID-19 大流行对新诊断出的痴呆症数量以及痴呆症诊断和治疗质量的影响
IF 6.4 Q2 BUSINESS Pub Date : 2024-08-10 DOI: 10.14283/jpad.2024.150
M. T. Hoang, P. G. Jurado, T. Abzhandadze, S. Mostafaei, M. Mo, M. Åkerman, K. Vestling, C. Chen, H. Xu, M. Eriksdotter, Sara Garcia-Ptacek

Background

Care trajectories were disrupted during the COVID-19 pandemic. However, how COVID-19 influenced the number of new dementia diagnoses, and the quality of dementia work-ups, and treatment is understudied.

Objective

To investigate the change in new dementia registrations, diagnostics, and treatment in the pre-, COVID-19 and post-COVID-19 pandemic periods.

Design

A nationwide cohort study.

Setting

This population-based study used data from the Swedish Registry for Cognitive/Dementia disorders - SveDem, and other nationwide registries in Sweden.

Participants

Persons with dementia diagnosed between 2019 and 2021 were divided into three groups based on the date of diagnosis

the pre-COVID-19 period (01 January 2019 – 29 February 2020), the COVID-19 period (01 March 2020 – 31 December 2020), and the post-COVID-19 period (01 January 2021 – 31 August 2021).

Measurements

Outcomes included dementia diagnostics and treatments.

Results

The monthly average number of new dementia cases registered in SveDem was 595, 415 and 470, respectively in the pre-COVID-19, COVID-19 and post-COVID-19 period. Compared to the pre-COVID-19 period, the monthly number of registrations decreased, but provision of the basic diagnostic work-up, its individual tests, and the use of cholinesterase inhibitors, memantine and antipsychotics were not significantly different in the COVID-19 period. Compared to the pre-COVID-19 period, new dementia diagnoses continued to be low in the post-COVID-19 period, but diagnosed individuals were more likely to receive the complete basic diagnostic work-up (OR 1.14, 95% CI 1.00–1.29), blood analysis (OR 1.88, 95% CI 1.44–2.49), computed tomography and magnetic resonance imaging (OR 1.22, 95% CI 1.01–1.48), occupational therapy assessment (OR 1.13, 95% CI 1.04–1.22), and memantine (OR 1.19, 95% CI 1.07–1.31).

Conclusion

The quantity of new dementia registrations in SveDem decreased in the COVID-19 period and has not returned to pre-COVID-19 levels, but the quality of the work-ups which were conducted and registered in SveDem was similar or higher than in the pre-COVID-19 period. It is imperative to implement policies to increase SveDem registration with the aim of matching or exceeding pre-COVID-19 levels.

背景在 COVID-19 大流行期间,护理轨迹被打乱。目标调查 COVID-19 流行前、COVID-19 流行后和 COVID-19 流行后新痴呆症登记、诊断和治疗的变化。参与者2019年至2021年期间确诊的痴呆症患者根据确诊日期分为三组:COVID-19前时期(2019年1月1日至2020年2月29日)、COVID-19时期(2020年3月1日至2020年12月31日)和COVID-19后时期(2021年1月1日至2021年8月31日)。结果在 COVID-19 之前、COVID-19 期间和 COVID-19 之后,SveDem 登记的新痴呆病例月平均数量分别为 595 例、415 例和 470 例。与 COVID-19 前相比,每月登记的病例数有所减少,但在 COVID-19 期间,基本诊断工作的提供、单项检测以及胆碱酯酶抑制剂、美金刚和抗精神病药物的使用均无显著差异。与 COVID-19 前相比,COVID-19 后新诊断出的痴呆症患者人数仍然较少,但已确诊的患者更有可能接受完整的基本诊断检查(OR 1.14,95% CI 1.00-1.29)、血液分析(OR 1.88,95% CI 1.44-2.49)、计算机断层扫描和磁共振成像(OR 1.22,95% CI 1.01-1.48)、职业治疗评估(OR 1.88,95% CI 1.44-2.49)。结论在 COVID-19 期间,SveDem 中新登记的痴呆症患者数量有所减少,且尚未恢复到 COVID-19 之前的水平,但在 SveDem 中进行和登记的工作检查的质量与 COVID-19 之前的水平相似或更高。当务之急是执行增加 SveDem 登记的政策,以达到或超过 19 年前的水平。
{"title":"Effects of the COVID-19 Pandemic on the Number of New Dementia Diagnoses and the Quality of Dementia Diagnostics and Treatment","authors":"M. T. Hoang, P. G. Jurado, T. Abzhandadze, S. Mostafaei, M. Mo, M. Åkerman, K. Vestling, C. Chen, H. Xu, M. Eriksdotter, Sara Garcia-Ptacek","doi":"10.14283/jpad.2024.150","DOIUrl":"https://doi.org/10.14283/jpad.2024.150","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Care trajectories were disrupted during the COVID-19 pandemic. However, how COVID-19 influenced the number of new dementia diagnoses, and the quality of dementia work-ups, and treatment is understudied.</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To investigate the change in new dementia registrations, diagnostics, and treatment in the pre-, COVID-19 and post-COVID-19 pandemic periods.</p><h3 data-test=\"abstract-sub-heading\">Design</h3><p>A nationwide cohort study.</p><h3 data-test=\"abstract-sub-heading\">Setting</h3><p>This population-based study used data from the Swedish Registry for Cognitive/Dementia disorders - SveDem, and other nationwide registries in Sweden.</p><h3 data-test=\"abstract-sub-heading\">Participants</h3><p>Persons with dementia diagnosed between 2019 and 2021 were divided into three groups based on the date of diagnosis</p><p>the pre-COVID-19 period (01 January 2019 – 29 February 2020), the COVID-19 period (01 March 2020 – 31 December 2020), and the post-COVID-19 period (01 January 2021 – 31 August 2021).</p><h3 data-test=\"abstract-sub-heading\">Measurements</h3><p>Outcomes included dementia diagnostics and treatments.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The monthly average number of new dementia cases registered in SveDem was 595, 415 and 470, respectively in the pre-COVID-19, COVID-19 and post-COVID-19 period. Compared to the pre-COVID-19 period, the monthly number of registrations decreased, but provision of the basic diagnostic work-up, its individual tests, and the use of cholinesterase inhibitors, memantine and antipsychotics were not significantly different in the COVID-19 period. Compared to the pre-COVID-19 period, new dementia diagnoses continued to be low in the post-COVID-19 period, but diagnosed individuals were more likely to receive the complete basic diagnostic work-up (OR 1.14, 95% CI 1.00–1.29), blood analysis (OR 1.88, 95% CI 1.44–2.49), computed tomography and magnetic resonance imaging (OR 1.22, 95% CI 1.01–1.48), occupational therapy assessment (OR 1.13, 95% CI 1.04–1.22), and memantine (OR 1.19, 95% CI 1.07–1.31).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The quantity of new dementia registrations in SveDem decreased in the COVID-19 period and has not returned to pre-COVID-19 levels, but the quality of the work-ups which were conducted and registered in SveDem was similar or higher than in the pre-COVID-19 period. It is imperative to implement policies to increase SveDem registration with the aim of matching or exceeding pre-COVID-19 levels.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"75 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141929868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining the Role of Community Engagement in Enhancing the Participation of Racial and Ethnic Minoritized Communities in Alzheimer’s Disease Clinical Trials; A Rapid Review 研究社区参与在促进少数种族和族裔社区参与阿尔茨海默病临床试验中的作用;快速综述
IF 6.4 Q2 BUSINESS Pub Date : 2024-08-09 DOI: 10.14283/jpad.2024.149
Sanaz Dabiri, R. Raman, J. Grooms, D. Molina-Henry

Background

Despite higher dementia prevalence in racial and ethnic minoritized communities, they are underrepresented in Alzheimer’s disease clinical trials. Community-based recruitment strategies are believed to yield positive outcomes in various fields, such as cancer and cardiovascular clinical trials, but their outcomes in Alzheimer’s disease and Related Dementias (AD/ADRD) require further study. In this systematic rapid review, we synthesized the available evidence on community-engaged recruitment strategies in enhancing participation in AD/ADRD clinical trials and observational study participation.

Methods

We searched and identified studies describing a community-based recruitment approach for racial and ethnic minoritized communities across seven databases (Pubmed, OVID MEDLINE, Cochrane Central Register of Controlled Trials, CINAHL, PsychINFO, Web of Science, and EMBASE).

Results

Out of 1915 screened studies, 49 met the inclusion criteria. Most studies employed multiple community-based recruitment approaches, including educational presentations, collaborations with community-based faith organizations, community advisory boards, and engagement with local clinics or health professionals. 52% of studies targeted more than one racial and ethnic minoritized population, primarily African Americans and then Hispanic/Latino. Gaps in knowledge about AD/ADRD, its increased risk among minoritized populations, distrust, and stigma were noted as barriers to research participation. Approximately 50% of the studies specified whether they evaluated their recruitment approaches, and in studies where approaches were evaluated, there was substantial heterogeneity in methods utilized.

Conclusion

The quality of available evidence on the use of community-based recruitment approaches to include racial and ethnic minoritized populations in AD/ADRD research, particularly in clinical trials, is limited. Systematic assessment of recruitment strategies is urgently needed to increase the evidence base around community-engaged recruitment approaches.

背景尽管少数种族和族裔社区的痴呆症发病率较高,但他们在阿尔茨海默病临床试验中的代表性却不足。以社区为基础的招募策略被认为在癌症和心血管临床试验等多个领域产生了积极的效果,但其在阿尔茨海默病及相关痴呆症(AD/ADRD)中的效果还需要进一步研究。在这篇系统性的快速综述中,我们综合了社区参与招募策略在提高 AD/ADRD 临床试验参与度和观察性研究参与度方面的现有证据。方法我们在 7 个数据库(Pubmed、OVID MEDLINE、Cochrane Central Register of Controlled Trials、CINAHL、PsychINFO、Web of Science 和 EMBASE)中搜索并确定了针对少数种族和族裔社区的社区招募方法的研究。大多数研究采用了多种基于社区的招募方法,包括教育演讲、与社区信仰组织合作、社区咨询委员会以及与当地诊所或医疗专业人员合作。52% 的研究针对一个以上的少数种族和族裔人群,主要是非裔美国人,然后是西班牙裔/拉丁美洲人。人们注意到,对注意力缺失症/注意力缺失性痴呆症的认识不足、其在少数民族人群中的风险增加、不信任和耻辱感是参与研究的障碍。约50%的研究明确说明了他们是否对招募方法进行了评估,而在对招募方法进行评估的研究中,所使用的方法存在很大的不一致性。迫切需要对招募策略进行系统评估,以增加社区参与招募方法的证据基础。
{"title":"Examining the Role of Community Engagement in Enhancing the Participation of Racial and Ethnic Minoritized Communities in Alzheimer’s Disease Clinical Trials; A Rapid Review","authors":"Sanaz Dabiri, R. Raman, J. Grooms, D. Molina-Henry","doi":"10.14283/jpad.2024.149","DOIUrl":"https://doi.org/10.14283/jpad.2024.149","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Despite higher dementia prevalence in racial and ethnic minoritized communities, they are underrepresented in Alzheimer’s disease clinical trials. Community-based recruitment strategies are believed to yield positive outcomes in various fields, such as cancer and cardiovascular clinical trials, but their outcomes in Alzheimer’s disease and Related Dementias (AD/ADRD) require further study. In this systematic rapid review, we synthesized the available evidence on community-engaged recruitment strategies in enhancing participation in AD/ADRD clinical trials and observational study participation.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We searched and identified studies describing a community-based recruitment approach for racial and ethnic minoritized communities across seven databases (Pubmed, OVID MEDLINE, Cochrane Central Register of Controlled Trials, CINAHL, PsychINFO, Web of Science, and EMBASE).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Out of 1915 screened studies, 49 met the inclusion criteria. Most studies employed multiple community-based recruitment approaches, including educational presentations, collaborations with community-based faith organizations, community advisory boards, and engagement with local clinics or health professionals. 52% of studies targeted more than one racial and ethnic minoritized population, primarily African Americans and then Hispanic/Latino. Gaps in knowledge about AD/ADRD, its increased risk among minoritized populations, distrust, and stigma were noted as barriers to research participation. Approximately 50% of the studies specified whether they evaluated their recruitment approaches, and in studies where approaches were evaluated, there was substantial heterogeneity in methods utilized.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The quality of available evidence on the use of community-based recruitment approaches to include racial and ethnic minoritized populations in AD/ADRD research, particularly in clinical trials, is limited. Systematic assessment of recruitment strategies is urgently needed to increase the evidence base around community-engaged recruitment approaches.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"16 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141929867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform 利用 Lumipulse 平台检测血浆 p-tau217 对认知功能未受损受试者脑脊液病理变化的诊断准确性
IF 6.4 Q2 BUSINESS Pub Date : 2024-08-07 DOI: 10.14283/jpad.2024.152
Francisco Martínez-Dubarbie, A. Guerra-Ruiz, S. López-García, C. Lage, M. Fernández-Matarrubia, J. Infante, A. Pozueta-Cantudo, M. García-Martínez, A. Corrales-Pardo, M. Bravo, M. López-Hoyos, J. Irure-Ventura, E. Valeriano-Lorenzo, M. T. García-Unzueta, P. Sánchez-Juan, E. Rodríguez-Rodríguez

Background

Plasma biomarkers of Alzheimer’s disease (AD), especially p-tau217, are promising tools to identify subjects with amyloid deposition in the brain, determined either by cerebrospinal fluid (CSF) or positron emission tomography. However, it is essential to measure them in an accurate and fully automated way in order to apply them in clinical practice.

Objectives

To evaluate the diagnostic performance of the fully-automated Lumipulse plasma p-tau217 assay in preclinical AD.

Design

Cross-sectional analyses from a prospective cohort.

Setting

A population-based study.

Participants

Volunteers over 55 years without cognitive impairment or contraindications for complementary tests.

Measurements

Plasma p-tau217 was measured with the fully-automated Lumipulse assay, as well as CSF Aβ40, Aβ42, p-taul81, and t-tau levels. We correlated plasma p-tau217 with CSF Aβ40, Aβ42 and p-tau181, and assessed the differences in plasma p-tau217 according to CSF amyloid status (A−/+), AD status (AD+ being those subjects A+T+ and AD- the rest) and ATN group. We performed ROC curves and measured the areas under the curve (AUC) using CSF amyloid as result, and both p-tau217 and ApoE4 status as predictor.

Results

We screened 209 cognitively unimpaired volunteers with a mean age 64 years (60–69) and 30.2% of ApoE4 carriers. Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho=−0.51; p-value<0.001) and p-tau181 (r=0.59; p-value<0.001). Its levels were significantly higher in A+ subjects (0.26 pg/ml) compared with A- (0.12 pg/ml; p-value<0.001); and along ATN groups. It predicts CSF amyloid pathology with an AUC of 0.85.

Conclusions

Plasma p-tau217 measured using the Lumipulse platform shows promise as an accurate biomarker of preclinical AD pathology.

背景阿尔茨海默病(AD)的血浆生物标记物,尤其是p-tau217,是通过脑脊液(CSF)或正电子发射断层扫描确定脑内淀粉样蛋白沉积受试者的有前途的工具。目的 评估全自动 Lumipulse 血浆 p-tau217 检测法在临床前 AD 中的诊断性能。参与者55岁以上、无认知障碍或辅助检查禁忌症的志愿者。测量采用全自动鲁米帕斯检测法测量血浆p-tau217以及脑脊液Aβ40、Aβ42、p-taul81和t-tau水平。我们将血浆p-tau217与CSF Aβ40、Aβ42和p-tau181相关联,并根据CSF淀粉样状态(A-/+)、AD状态(AD+为A+T+受试者,其余为AD-受试者)和ATN组评估血浆p-tau217的差异。我们以 CSF 淀粉样蛋白为结果,以 p-tau217 和载脂蛋白 E4 状态为预测因子,绘制了 ROC 曲线并测量了曲线下面积(AUC)。血浆 p-tau217 与脑脊液 Aβ42/Aβ40 (Rho=-0.51; p-value<0.001) 和 p-tau181 (r=0.59; p-value<0.001) 显著相关。与 A- 组(0.12 pg/ml;p 值<0.001)相比,A+ 组(0.26 pg/ml)和 ATN 组(0.12 pg/ml;p 值<0.001)的淀粉样蛋白水平明显更高。结论使用 Lumipulse 平台测量的血浆 p-tau217 有希望成为临床前 AD 病理学的准确生物标记物。
{"title":"Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform","authors":"Francisco Martínez-Dubarbie, A. Guerra-Ruiz, S. López-García, C. Lage, M. Fernández-Matarrubia, J. Infante, A. Pozueta-Cantudo, M. García-Martínez, A. Corrales-Pardo, M. Bravo, M. López-Hoyos, J. Irure-Ventura, E. Valeriano-Lorenzo, M. T. García-Unzueta, P. Sánchez-Juan, E. Rodríguez-Rodríguez","doi":"10.14283/jpad.2024.152","DOIUrl":"https://doi.org/10.14283/jpad.2024.152","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Plasma biomarkers of Alzheimer’s disease (AD), especially p-tau217, are promising tools to identify subjects with amyloid deposition in the brain, determined either by cerebrospinal fluid (CSF) or positron emission tomography. However, it is essential to measure them in an accurate and fully automated way in order to apply them in clinical practice.</p><h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>To evaluate the diagnostic performance of the fully-automated Lumipulse plasma p-tau217 assay in preclinical AD.</p><h3 data-test=\"abstract-sub-heading\">Design</h3><p>Cross-sectional analyses from a prospective cohort.</p><h3 data-test=\"abstract-sub-heading\">Setting</h3><p>A population-based study.</p><h3 data-test=\"abstract-sub-heading\">Participants</h3><p>Volunteers over 55 years without cognitive impairment or contraindications for complementary tests.</p><h3 data-test=\"abstract-sub-heading\">Measurements</h3><p>Plasma p-tau217 was measured with the fully-automated Lumipulse assay, as well as CSF Aβ40, Aβ42, p-taul81, and t-tau levels. We correlated plasma p-tau217 with CSF Aβ40, Aβ42 and p-tau181, and assessed the differences in plasma p-tau217 according to CSF amyloid status (A−/+), AD status (AD+ being those subjects A+T+ and AD- the rest) and ATN group. We performed ROC curves and measured the areas under the curve (AUC) using CSF amyloid as result, and both p-tau217 and ApoE4 status as predictor.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>We screened 209 cognitively unimpaired volunteers with a mean age 64 years (60–69) and 30.2% of ApoE4 carriers. Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho=−0.51; p-value&lt;0.001) and p-tau181 (r=0.59; p-value&lt;0.001). Its levels were significantly higher in A+ subjects (0.26 pg/ml) compared with A- (0.12 pg/ml; p-value&lt;0.001); and along ATN groups. It predicts CSF amyloid pathology with an AUC of 0.85.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Plasma p-tau217 measured using the Lumipulse platform shows promise as an accurate biomarker of preclinical AD pathology.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"79 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141929877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer’s Disease CT1812 治疗对轻度至中度阿尔茨海默病患者突触活动影响的脑电图试验研究
IF 6.4 Q2 BUSINESS Pub Date : 2024-08-07 DOI: 10.14283/jpad.2024.154
E. Vijverberg, W. de Haan, E. Scheijbeler, M. E. Hamby, S. Catalano, P. Scheltens, M. Grundman, Anthony O. Caggiano

Background

CT1812 is a first-in-class, sigma-2 receptor ligand, that prevents and displaces binding of amyloid beta (Aβ) oligomers. Normalization of quantitative electroencephalography (qEEG) markers suggests that CT1812 protects synapses from Aβ oligomer toxicity.

Objectives

Evaluate CT1812 impact on synaptic function using qEEG measurements.

Design

Phase 2, randomized, double-blind, placebo-controlled, 4-week crossover study.

Setting

VU University Medical Center and Brain Research Center Amsterdam, The Netherlands.

Participants

Adults with mild or moderate Alzheimer’s disease (AD).

Intervention

A daily 300 mg dose of CT1812 or placebo for 4 weeks.

Measurements

A resting-state, eyes closed qEEG assessment occurred on Day 1 and on Day 29 of Treatment Periods 1 and 2, and at follow-up. The primary endpoint was global relative theta power (4–8 Hz), along with secondary EEG measures including global alpha corrected Amplitude Envelope Correlation (AEC-c). Cognitive and functional assessments, fluid biomarkers, and safety and tolerability were assessed.

Results

16 patients were randomized, and 15 completed. A non-significant (p=0.123) but consistent reduction occurred in global relative theta power and in relative theta power in frontal, temporal, parietal, occipital and central (p<0.006) brain regions with CT1812. A nominally significant (p=0.034) improvement was observed in global alpha AEC-c. Adverse events occurred in 11 patients with CT1812 and 6 with placebo -most commonly nausea, diarrhea, and procedural headache. No severe or serious AEs, deaths or discontinuations were reported.

Conclusion

CT1812 improved established EEG markers of spontaneous brain activity (spectral power, functional connectivity) in patients with mild-to-moderate AD, suggesting improved neuronal/synaptic function within a 4-week timespan.

背景CT1812是一种首创的σ-2受体配体,它能阻止和取代淀粉样β(Aβ)寡聚体的结合。定量脑电图(qEEG)标记物的正常化表明,CT1812能保护突触免受Aβ寡聚体毒性的影响。目标通过qEEG测量评估CT1812对突触功能的影响。设计第二阶段、随机、双盲、安慰剂对照、4周交叉研究。干预每天服用 300 毫克 CT1812 或安慰剂,为期 4 周。测量在治疗期 1 和 2 的第 1 天和第 29 天以及随访时进行静息状态、闭眼 qEEG 评估。主要终点是全局相对θ功率(4-8赫兹),次要脑电图测量包括全局α校正振幅包络相关性(AEC-c)。此外,还对认知和功能评估、体液生物标志物以及安全性和耐受性进行了评估。CT1812 可显著(p=0.123)但一致地降低整体相对 Theta 功率,以及额叶、颞叶、顶叶、枕叶和中央脑区的相对 Theta 功率(p<0.006)。全局阿尔法AEC-c也有明显改善(p=0.034)。11名患者使用CT1812后出现了不良反应,6名患者使用安慰剂后出现了不良反应--最常见的是恶心、腹泻和程序性头痛。结论 CT1812 改善了轻度至中度 AD 患者自发脑活动的脑电图标记(频谱功率、功能连接),表明在 4 周时间内神经元/突触功能得到改善。
{"title":"A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer’s Disease","authors":"E. Vijverberg, W. de Haan, E. Scheijbeler, M. E. Hamby, S. Catalano, P. Scheltens, M. Grundman, Anthony O. Caggiano","doi":"10.14283/jpad.2024.154","DOIUrl":"https://doi.org/10.14283/jpad.2024.154","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>CT1812 is a first-in-class, sigma-2 receptor ligand, that prevents and displaces binding of amyloid beta (Aβ) oligomers. Normalization of quantitative electroencephalography (qEEG) markers suggests that CT1812 protects synapses from Aβ oligomer toxicity.</p><h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>Evaluate CT1812 impact on synaptic function using qEEG measurements.</p><h3 data-test=\"abstract-sub-heading\">Design</h3><p>Phase 2, randomized, double-blind, placebo-controlled, 4-week crossover study.</p><h3 data-test=\"abstract-sub-heading\">Setting</h3><p>VU University Medical Center and Brain Research Center Amsterdam, The Netherlands.</p><h3 data-test=\"abstract-sub-heading\">Participants</h3><p>Adults with mild or moderate Alzheimer’s disease (AD).</p><h3 data-test=\"abstract-sub-heading\">Intervention</h3><p>A daily 300 mg dose of CT1812 or placebo for 4 weeks.</p><h3 data-test=\"abstract-sub-heading\">Measurements</h3><p>A resting-state, eyes closed qEEG assessment occurred on Day 1 and on Day 29 of Treatment Periods 1 and 2, and at follow-up. The primary endpoint was global relative theta power (4–8 Hz), along with secondary EEG measures including global alpha corrected Amplitude Envelope Correlation (AEC-c). Cognitive and functional assessments, fluid biomarkers, and safety and tolerability were assessed.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>16 patients were randomized, and 15 completed. A non-significant (p=0.123) but consistent reduction occurred in global relative theta power and in relative theta power in frontal, temporal, parietal, occipital and central (p&lt;0.006) brain regions with CT1812. A nominally significant (p=0.034) improvement was observed in global alpha AEC-c. Adverse events occurred in 11 patients with CT1812 and 6 with placebo -most commonly nausea, diarrhea, and procedural headache. No severe or serious AEs, deaths or discontinuations were reported.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>CT1812 improved established EEG markers of spontaneous brain activity (spectral power, functional connectivity) in patients with mild-to-moderate AD, suggesting improved neuronal/synaptic function within a 4-week timespan.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"100 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141929870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Informing Alzheimer’s Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure 阿尔茨海默氏症生物标志物交流的信息:认知能力未受损的成年人在淀粉样蛋白结果披露期间的担忧和理解
IF 6.4 Q2 BUSINESS Pub Date : 2024-08-07 DOI: 10.14283/jpad.2024.151
Fred B. Ketchum, C. M. Erickson, K. E. Basche, N. A. Chin, M. L. Eveler, C. E. Conway, D. M. Coughlin, L. R. Clark

Background

Biomarker results are increasingly disclosed in research and clinical settings, but less is known about how individuals interpret their results or concerns raised during the disclosure visit that may need to be addressed by clinicians to ensure appropriate disclosure.

Methods

Fifty-two cognitively unimpaired older adults aged 65 to 89 years old from the Wisconsin Registry for Alzheimer’s Prevention, who had undergone an amyloid PET scan in the previous 18 months, were enrolled in the disclosure substudy. After ensuring psychological readiness, trained study clinicians disclosed amyloid PET results using a structured protocol. We assessed participants’ level of understanding, concerns, and the perceived personal significance of their biomarker results during the disclosure visit through a series of question prompts in real-time.

Results

Thirty-four received a non-elevated amyloid result and 18 received an elevated result. The average age was 72.2 years (range 65–81); most were women (64%) and non-Hispanic White (92%). Participants understood their results (98%), and both non-elevated and elevated groups provided similar responses around topics of sharing with others, privacy, accuracy of testing, and risk. Participants with elevated results were significantly more likely than those with non-elevated results to want to change their lifestyle (78% vs 12%, p=<0.01) and have questions about their results (61% vs 30%, p=0.05). Participants interpreted the personal significance of results in terms of several themes relating to individual risk status, emotional impact, whether the result was expected, and prevention/planning.

Conclusion

Results show that participants understand their biomarker results, and have a number of concerns during the disclosure process that clinical and research protocols could address. en These findings could be important considerations as effective processes are developed for widespread biomarker disclosure in clinical and research settings.

背景生物标记物结果越来越多地在研究和临床环境中披露,但人们对个人如何解释他们的结果或在披露访问期间提出的顾虑却知之甚少,而这些顾虑可能需要临床医生来解决,以确保适当的披露。方法威斯康星州阿尔茨海默氏症预防登记处的 52 名认知功能未受损的 65-89 岁老年人参加了披露子研究,他们在过去 18 个月中接受了淀粉样蛋白 PET 扫描。在确保做好心理准备后,经过培训的研究临床医生采用结构化协议披露淀粉样蛋白 PET 结果。在披露过程中,我们通过一系列实时问题提示来评估参与者对其生物标志物结果的理解程度、担忧和感知到的个人意义。结果34人的淀粉样蛋白结果未升高,18人的结果升高。参与者的平均年龄为 72.2 岁(65-81 岁不等);大多数为女性(64%)和非西班牙裔白人(92%)。参与者了解自己的结果(98%),未升高组和升高组对与他人分享、隐私、检测的准确性和风险等话题的回答相似。结果升高的参与者希望改变生活方式(78% 对 12%,p=0.01)和对结果有疑问(61% 对 30%,p=0.05)的可能性明显高于结果未升高的参与者。结果表明,参与者了解他们的生物标记物结果,并在披露过程中提出了一些临床和研究方案可以解决的问题。 这些发现可能是在临床和研究环境中为广泛披露生物标记物而开发有效流程时的重要考虑因素。
{"title":"Informing Alzheimer’s Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure","authors":"Fred B. Ketchum, C. M. Erickson, K. E. Basche, N. A. Chin, M. L. Eveler, C. E. Conway, D. M. Coughlin, L. R. Clark","doi":"10.14283/jpad.2024.151","DOIUrl":"https://doi.org/10.14283/jpad.2024.151","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Biomarker results are increasingly disclosed in research and clinical settings, but less is known about how individuals interpret their results or concerns raised during the disclosure visit that may need to be addressed by clinicians to ensure appropriate disclosure.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Fifty-two cognitively unimpaired older adults aged 65 to 89 years old from the Wisconsin Registry for Alzheimer’s Prevention, who had undergone an amyloid PET scan in the previous 18 months, were enrolled in the disclosure substudy. After ensuring psychological readiness, trained study clinicians disclosed amyloid PET results using a structured protocol. We assessed participants’ level of understanding, concerns, and the perceived personal significance of their biomarker results during the disclosure visit through a series of question prompts in real-time.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Thirty-four received a non-elevated amyloid result and 18 received an elevated result. The average age was 72.2 years (range 65–81); most were women (64%) and non-Hispanic White (92%). Participants understood their results (98%), and both non-elevated and elevated groups provided similar responses around topics of sharing with others, privacy, accuracy of testing, and risk. Participants with elevated results were significantly more likely than those with non-elevated results to want to change their lifestyle (78% vs 12%, p=&lt;0.01) and have questions about their results (61% vs 30%, p=0.05). Participants interpreted the personal significance of results in terms of several themes relating to individual risk status, emotional impact, whether the result was expected, and prevention/planning.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Results show that participants understand their biomarker results, and have a number of concerns during the disclosure process that clinical and research protocols could address. en These findings could be important considerations as effective processes are developed for widespread biomarker disclosure in clinical and research settings.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"45 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141929871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Causal Effect of Type 2 Diabetes on Alzheimer’s Disease Using Large-Scale Genetic Data 利用大规模遗传数据评估 2 型糖尿病对阿尔茨海默病的因果效应
IF 6.4 Q2 BUSINESS Pub Date : 2024-07-31 DOI: 10.14283/jpad.2024.148
D. Liu, A. Baranova, Fuquan Zhang

Background

Alzheimer’s disease (AD) has a high comorbidity with type 2 diabetes (T2D). However, there is still some controversy over whether T2D has a causal impact on AD at present.

Objectives

We aimed to reveal whether T2D has a causal effect on AD using large-scale genetic data.

Methods

Firstly, we performed a primary two-sample Mendelian randomization (MR) analysis to assess the potential causal effects of T2D on AD. For this analysis, we used the largest available genome-wide association studies (GWAS) T2D (T2D1, including 80,154 cases and 853,816 controls) and AD (AD1, including 111,326 cases and 677,663 controls) datasets. Additionally, we performed a validation MR analysis using two largely overlapping-sample datasets from FinnGen, including T2D (T2D2, including 57,698 cases and 308,252 controls) and AD (AD2, including 13,393 cases and 363,884 controls). In all MR analyses, the inverse variance-weighted method was used as the primary analysis method, supplemented by the weighted-median and MR-Egger techniques.

Results

In the primary analysis, we found that T2D was not associated with the risk of AD (OR: 0.98, CI: 0.95–1.01, P=0.241). Similarly, no significant association was detected in the validation MR analysis (OR: 0.97, CI: 0.64–1.47, P=0.884).

Conclusion

Our findings provide robust evidence that T2D does not have a causal impact on AD. Future studies need to further explore the effect of T2D on the non-AD components of the dementia phenotype.

背景阿尔茨海默病(AD)与 2 型糖尿病(T2D)的合并率很高。方法首先,我们进行了一次主要的双样本孟德尔随机化(MR)分析,以评估 T2D 对 AD 的潜在因果效应。在这项分析中,我们使用了现有最大的全基因组关联研究(GWAS)T2D(T2D1,包括 80154 个病例和 853816 个对照)和 AD(AD1,包括 111326 个病例和 677663 个对照)数据集。此外,我们还使用 FinnGen 的两个基本重叠的样本数据集进行了验证 MR 分析,包括 T2D(T2D2,包括 57,698 例病例和 308,252 例对照)和 AD(AD2,包括 13,393 例病例和 363,884 例对照)。在所有 MR 分析中,均以反方差加权法作为主要分析方法,并辅以加权中值法和 MR-Egger 技术。结果在主要分析中,我们发现 T2D 与 AD 风险无关(OR:0.98,CI:0.95-1.01,P=0.241)。同样,在验证性 MR 分析中也没有发现明显的关联(OR:0.97,CI:0.64-1.47,P=0.884)。未来的研究需要进一步探讨T2D对痴呆表型中非AD成分的影响。
{"title":"Evaluating the Causal Effect of Type 2 Diabetes on Alzheimer’s Disease Using Large-Scale Genetic Data","authors":"D. Liu, A. Baranova, Fuquan Zhang","doi":"10.14283/jpad.2024.148","DOIUrl":"https://doi.org/10.14283/jpad.2024.148","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Alzheimer’s disease (AD) has a high comorbidity with type 2 diabetes (T2D). However, there is still some controversy over whether T2D has a causal impact on AD at present.</p><h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>We aimed to reveal whether T2D has a causal effect on AD using large-scale genetic data.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Firstly, we performed a primary two-sample Mendelian randomization (MR) analysis to assess the potential causal effects of T2D on AD. For this analysis, we used the largest available genome-wide association studies (GWAS) T2D (T2D1, including 80,154 cases and 853,816 controls) and AD (AD1, including 111,326 cases and 677,663 controls) datasets. Additionally, we performed a validation MR analysis using two largely overlapping-sample datasets from FinnGen, including T2D (T2D2, including 57,698 cases and 308,252 controls) and AD (AD2, including 13,393 cases and 363,884 controls). In all MR analyses, the inverse variance-weighted method was used as the primary analysis method, supplemented by the weighted-median and MR-Egger techniques.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In the primary analysis, we found that T2D was not associated with the risk of AD (OR: 0.98, CI: 0.95–1.01, P=0.241). Similarly, no significant association was detected in the validation MR analysis (OR: 0.97, CI: 0.64–1.47, P=0.884).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Our findings provide robust evidence that T2D does not have a causal impact on AD. Future studies need to further explore the effect of T2D on the non-AD components of the dementia phenotype.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"63 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141783223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer’s Disease 阿杜单抗治疗早期阿尔茨海默病患者的 3 期临床试验 EMERGE 和 ENGAGE 的日本亚组分析报告
IF 6.4 Q2 BUSINESS Pub Date : 2024-07-27 DOI: 10.14283/jpad.2024.106
Yasuo Toda, T. Iwatsubo, Y. Nakamura, N. Matsuda, M. Miyata, M. Jin, T. Chen, K. Kuribayashi, Y. Tian, R. Hughes, J. Yamamoto, K. K. Muralidharan, C. Rubel, R. M. Hutchison, S. Budd Haeberlein
<h3 data-test="abstract-sub-heading">Background</h3><p>Global prevalence and incidence of dementia continue to rise at a rapid rate. There is a need for new Alzheimer’s disease (AD) treatments globally. Aducanumab is a human monoclonal antibody that selectively targets aggregated soluble amyloid beta oligomers and insoluble amyloid beta fibrils. In June 2021, aducanumab was approved by the US Food and Drug Administration for the treatment of AD under the accelerated approval pathway.</p><h3 data-test="abstract-sub-heading">Objectives</h3><p>We evaluated the efficacy, safety, biomarker and pharmacokinetics (PK) of aducanumab in Japanese subgroups in EMERGE and ENGAGE studies.</p><h3 data-test="abstract-sub-heading">Design</h3><p>EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early AD (mild cognitive impairment due to AD or mild AD dementia).</p><h3 data-test="abstract-sub-heading">Setting</h3><p>These studies involved 348 sites in 20 countries. PARTICIPANTS: Participants enrolled in Japan included 121 (7.4% of total 1638 in EMERGE) and 100 (6.1% of total 1647 in ENGAGE) patients (aged 50–85 years with confirmed amyloid pathology) who met clinical criteria for mild cognitive impairment due to AD or mild AD dementia.</p><h3 data-test="abstract-sub-heading">Intervention</h3><p>Participants were randomly assigned 1:1:1 to receive aducanumab low dose (3 or 6 mg/kg target dose), high dose (6 or 10 mg/kg target dose) or placebo via IV infusion once every 4 weeks over 76 weeks.</p><h3 data-test="abstract-sub-heading">Measurements</h3><p>The primary outcome measure was change from baseline to Week 78 on the Clinical Dementia Rating Sum of Boxes (CDR-SB), an integrated scale that assesses both function and cognition. Other measures included safety assessments; secondary and tertiary clinical outcomes that assessed cognition, function, and behavior; biomarker endpoints (amyloid PET and plasma p-tau181); serum PK profiles and immunogenicity.</p><h3 data-test="abstract-sub-heading">Results</h3><p>Results from the Japanese subgroup analyses were generally consistent with those of the overall study population across endpoints, while a lower mean body weight (kg) and a smaller proportion of ApoE ε4 carriers were observed in the Japanese subgroup population. A treatment effect was observed in favor of aducanumab on the primary and secondary efficacy endpoints at Week 78 in EMERGE, but not ENGAGE. The incidence and type of adverse events in the Japanese subgroups were generally comparable to those observed in the overall study population; amyloid related imaging abnormalities (ARIA) were common treatment-related adverse events that appeared to be related to the aducanumab dose. ARIA incidence was generally lower in the Japanese subgroup compared with the overall population. Consistent with the overall data set, a robust dose-dependent decrease in amyloid beta levels as assessed with am
背景全球痴呆症的流行率和发病率继续快速上升。全球都需要新的阿尔茨海默病(AD)治疗方法。阿杜单抗是一种人类单克隆抗体,可选择性地靶向聚集的可溶性淀粉样 beta 低聚物和不溶性淀粉样 beta 纤维。目标我们评估了EMERGE和ENGAGE研究中日本亚组中阿杜库单抗的疗效、安全性、生物标志物和药代动力学(PK)。设计EMERGE和ENGAGE是针对早期AD(AD导致的轻度认知障碍或轻度AD痴呆)患者进行的两项随机、双盲、安慰剂对照、全球性3期研究。参与者在日本注册的参与者包括121名(占EMERGE研究总人数1638名的7.4%)和100名(占ENGAGE研究总人数1647名的6.1%)符合AD或轻度AD痴呆所致轻度认知障碍临床标准的患者(年龄在50-85岁之间,确诊有淀粉样病变)。干预参与者按1:1:1的比例随机分配接受阿杜单抗低剂量(3或6毫克/千克目标剂量)、高剂量(6或10毫克/千克目标剂量)或安慰剂静脉输注,每4周1次,共76周。测量主要结果是临床痴呆评级方框总和(CDR-SB)从基线到第78周的变化,这是一种评估功能和认知的综合量表。其他指标包括安全性评估;评估认知、功能和行为的二级和三级临床结果;生物标志物终点(淀粉样蛋白PET和血浆p-tau181);血清PK谱和免疫原性。结果日本亚组的分析结果与总体研究人群的终点结果基本一致,但观察到日本亚组人群的平均体重(公斤)较低,载脂蛋白E ε4携带者的比例较小。在EMERGE和ENGAGE研究中,在第78周的主要和次要疗效终点上观察到了有利于阿杜单抗的治疗效果。日本亚组的不良事件发生率和类型与总体研究人群中观察到的不良事件发生率和类型基本相当;淀粉样蛋白相关成像异常(ARIA)是常见的治疗相关不良事件,似乎与阿杜卡单抗的剂量有关。与总体研究人群相比,日本亚组的ARIA发生率普遍较低。通过淀粉样蛋白-PET和血浆p-tau181评估发现,淀粉样蛋白β水平的下降呈剂量依赖性,这与总体数据集一致。阿杜单抗在日本人群中的血清PK谱和免疫原性与非日本人群一致。在 EMERGE 中观察到阿杜单抗对疗效终点有积极的治疗作用,但在 ENGAGE 中没有观察到这种作用。
{"title":"Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer’s Disease","authors":"Yasuo Toda, T. Iwatsubo, Y. Nakamura, N. Matsuda, M. Miyata, M. Jin, T. Chen, K. Kuribayashi, Y. Tian, R. Hughes, J. Yamamoto, K. K. Muralidharan, C. Rubel, R. M. Hutchison, S. Budd Haeberlein","doi":"10.14283/jpad.2024.106","DOIUrl":"https://doi.org/10.14283/jpad.2024.106","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Background&lt;/h3&gt;&lt;p&gt;Global prevalence and incidence of dementia continue to rise at a rapid rate. There is a need for new Alzheimer’s disease (AD) treatments globally. Aducanumab is a human monoclonal antibody that selectively targets aggregated soluble amyloid beta oligomers and insoluble amyloid beta fibrils. In June 2021, aducanumab was approved by the US Food and Drug Administration for the treatment of AD under the accelerated approval pathway.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Objectives&lt;/h3&gt;&lt;p&gt;We evaluated the efficacy, safety, biomarker and pharmacokinetics (PK) of aducanumab in Japanese subgroups in EMERGE and ENGAGE studies.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Design&lt;/h3&gt;&lt;p&gt;EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early AD (mild cognitive impairment due to AD or mild AD dementia).&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Setting&lt;/h3&gt;&lt;p&gt;These studies involved 348 sites in 20 countries. PARTICIPANTS: Participants enrolled in Japan included 121 (7.4% of total 1638 in EMERGE) and 100 (6.1% of total 1647 in ENGAGE) patients (aged 50–85 years with confirmed amyloid pathology) who met clinical criteria for mild cognitive impairment due to AD or mild AD dementia.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Intervention&lt;/h3&gt;&lt;p&gt;Participants were randomly assigned 1:1:1 to receive aducanumab low dose (3 or 6 mg/kg target dose), high dose (6 or 10 mg/kg target dose) or placebo via IV infusion once every 4 weeks over 76 weeks.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Measurements&lt;/h3&gt;&lt;p&gt;The primary outcome measure was change from baseline to Week 78 on the Clinical Dementia Rating Sum of Boxes (CDR-SB), an integrated scale that assesses both function and cognition. Other measures included safety assessments; secondary and tertiary clinical outcomes that assessed cognition, function, and behavior; biomarker endpoints (amyloid PET and plasma p-tau181); serum PK profiles and immunogenicity.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Results&lt;/h3&gt;&lt;p&gt;Results from the Japanese subgroup analyses were generally consistent with those of the overall study population across endpoints, while a lower mean body weight (kg) and a smaller proportion of ApoE ε4 carriers were observed in the Japanese subgroup population. A treatment effect was observed in favor of aducanumab on the primary and secondary efficacy endpoints at Week 78 in EMERGE, but not ENGAGE. The incidence and type of adverse events in the Japanese subgroups were generally comparable to those observed in the overall study population; amyloid related imaging abnormalities (ARIA) were common treatment-related adverse events that appeared to be related to the aducanumab dose. ARIA incidence was generally lower in the Japanese subgroup compared with the overall population. Consistent with the overall data set, a robust dose-dependent decrease in amyloid beta levels as assessed with am","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"83 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141783224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daytime Sleepiness, Apnea, Neuroimaging Correlates and Cortisol Dysregulation in a Memory Clinic Cohort 记忆门诊队列中的白天嗜睡、呼吸暂停、神经影像学相关性和皮质醇失调
IF 6.4 Q2 BUSINESS Pub Date : 2024-07-18 DOI: 10.14283/jpad.2024.145
Charlotte Sørensen, I. Kåreholt, G. Kalpouzos, C. T. Udeh-Momoh, J. Holleman, M. Aspö, G. Hagman, G. Spulber, M. Kivipelto, A. Solomon, S. Sindi

Background

Sleep disturbances as well as cortisol hypersecretion are increasingly acknowledged as risk factors for Alzheimer’s disease (AD). However, the mechanisms underlying the association, and the interplay with cortisol abnormalities, remain unclear.

Objectives

This study aims to identify how self-reported sleep disturbances are associated with structural brain measures and diurnal cortisol dysregulation among memory clinic patients.

Design

A cross-sectional study performed at Karolinska University Hospital Memory Clinic, Sweden.

Participants

The study was based on 146 memory clinic patients diagnosed with either subjective cognitive impairment or mild cognitive impairment.

Measurements

Self-reported sleep was measured using the Karolinska Sleep Questionnaire. MRI or CT was used to quantify structural brain measures using four visual rating scales (Scheltens, Pasquier, Koedam, and Fazekas scales), and salivary cortisol was sampled to measure diurnal cortisol patterns through measures of cortisol immediately after awakening, cortisol awakening response, bedtime cortisol, total cortisol from awakening to bedtime, and the AM/PM cortisol ratio.

Results

Increased sleep apnea index (OR=1.20, 95% CI=1.04:1.39, p=0.015) was associated with greater odds of posterior brain atrophy, measured by the Koedam visual rating scale, and reduced awakening Cortisol (β=−0.03, 95% CI=− 0.07:0.00, p=0.045). Increased daytime sleepiness was associated with both reduced awakening cortisol (β=−0.03, 95% CI=−0.06:0.00, p=0.025) and a reduced AM/PM cortisol ratio (β=−0.04, CI=−0.08:−0.01, p= 0.021).

Conclusion

In a memory clinic cohort self-reported sleep disturbances are associated with both worse structural brain tissue integrity and altered diurnal cortisol profiles. These findings may add insights into possible mechanisms behind sleep disturbances in aging with subjective and cognitive impairment.

背景睡眠障碍和皮质醇分泌过多越来越被认为是阿尔茨海默病(AD)的风险因素。本研究旨在确定记忆门诊患者自我报告的睡眠障碍与大脑结构测量和皮质醇昼夜失调之间的关系。设计瑞典卡罗林斯卡大学医院记忆门诊进行了一项横断面研究。参与者本研究基于 146 名被诊断为主观认知障碍或轻度认知障碍的记忆门诊患者。采用核磁共振成像或 CT,使用四种视觉评分量表(Scheltens、Pasquier、Koedam 和 Fazekas 量表)对大脑结构进行量化测量,并采集唾液皮质醇样本,通过测量皮质醇唤醒后的立即皮质醇、皮质醇唤醒反应、睡前皮质醇、从唤醒到睡前的皮质醇总量以及上午/下午皮质醇比率来测量昼夜皮质醇模式。结果睡眠呼吸暂停指数增加(OR=1.20,95% CI=1.04:1.39,p=0.015)与科达姆视觉评分量表测量的后脑萎缩几率增加和觉醒皮质醇减少(β=-0.03,95% CI=-0.07:0.00,p=0.045)有关。白天嗜睡增加与觉醒皮质醇降低(β=-0.03,95% CI=-0.06:0.00,p=0.025)和上午/下午皮质醇比率降低(β=-0.04,CI=-0.08:-0.01,p=0.021)有关。这些发现可能有助于人们深入了解主观和认知功能受损的老年患者睡眠障碍背后的可能机制。
{"title":"Daytime Sleepiness, Apnea, Neuroimaging Correlates and Cortisol Dysregulation in a Memory Clinic Cohort","authors":"Charlotte Sørensen, I. Kåreholt, G. Kalpouzos, C. T. Udeh-Momoh, J. Holleman, M. Aspö, G. Hagman, G. Spulber, M. Kivipelto, A. Solomon, S. Sindi","doi":"10.14283/jpad.2024.145","DOIUrl":"https://doi.org/10.14283/jpad.2024.145","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Sleep disturbances as well as cortisol hypersecretion are increasingly acknowledged as risk factors for Alzheimer’s disease (AD). However, the mechanisms underlying the association, and the interplay with cortisol abnormalities, remain unclear.</p><h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>This study aims to identify how self-reported sleep disturbances are associated with structural brain measures and diurnal cortisol dysregulation among memory clinic patients.</p><h3 data-test=\"abstract-sub-heading\">Design</h3><p>A cross-sectional study performed at Karolinska University Hospital Memory Clinic, Sweden.</p><h3 data-test=\"abstract-sub-heading\">Participants</h3><p>The study was based on 146 memory clinic patients diagnosed with either subjective cognitive impairment or mild cognitive impairment.</p><h3 data-test=\"abstract-sub-heading\">Measurements</h3><p>Self-reported sleep was measured using the Karolinska Sleep Questionnaire. MRI or CT was used to quantify structural brain measures using four visual rating scales (Scheltens, Pasquier, Koedam, and Fazekas scales), and salivary cortisol was sampled to measure diurnal cortisol patterns through measures of cortisol immediately after awakening, cortisol awakening response, bedtime cortisol, total cortisol from awakening to bedtime, and the AM/PM cortisol ratio.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Increased sleep apnea index (OR=1.20, 95% CI=1.04:1.39, p=0.015) was associated with greater odds of posterior brain atrophy, measured by the Koedam visual rating scale, and reduced awakening Cortisol (β=−0.03, 95% CI=− 0.07:0.00, p=0.045). Increased daytime sleepiness was associated with both reduced awakening cortisol (β=−0.03, 95% CI=−0.06:0.00, p=0.025) and a reduced AM/PM cortisol ratio (β=−0.04, CI=−0.08:−0.01, p= 0.021).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>In a memory clinic cohort self-reported sleep disturbances are associated with both worse structural brain tissue integrity and altered diurnal cortisol profiles. These findings may add insights into possible mechanisms behind sleep disturbances in aging with subjective and cognitive impairment.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":"30 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141745597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The Journal of Prevention of Alzheimer's Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1